ADMA Biologics Competitors and Similar CompaniesClear all
ADMA Biologics's competitors and similar companies include CorMedix and Autolus.
 ADMA Biologics ADMA Biologics develops plasma-based biologics for the treatment and prevention of certain infectious diseases. |  CorMedix CorMedix is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney disease. |  Autolus Autolus Therapeutics is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products. | |
Founding Date | Founding Date 2004 | Founding Date 2006 | Founding Date 2014 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Ramsey, US HQ Boca Raton, US | Locations Berkeley Heights, US HQ | Locations London, GB HQ London, GB |
Employees | Employees 313 | Employees 3036% increase | Employees 647 |
Valuation ($) | Valuation ($) 3.9 b | Valuation ($) 749.2 m | Valuation ($) 1.2 b |
Financial | |||
Revenue (est.) | Revenue (est.) $510.2m (FY, 2025) | Revenue (est.) $311.7m (FY, 2025) | Revenue (est.) $75.4m (FY, 2025) |
Cost of goods | Cost of goods $217.4m (FY, 2025) | Cost of goods $22.1m (FY, 2025) | Cost of goods $86.6m (FY, 2025) |
Gross profit | Gross profit $292.8m (FY, 2025) | Gross profit $275.7m (FY, 2025) | Gross profit ($10.7m) (FY, 2025) |
Net income | Net income $146.9m (FY, 2025) | Net income $163.1m (FY, 2025) | Net income ($287.5m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 20m | Total funding raised $ 11.5m | Total funding raised $ 281.7m |
For sources of this data, please see the company profile
View Company Profiles
CorMedix
HQ
Berkeley Heights, US
Employees
30↑ 36% increase
CorMedix is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney disease.
View companyAutolus
HQ
London, GB
Employees
647
Autolus Therapeutics is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products.
View company